BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Tuesday, April 23, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Dec. 31, 2019
View Archived Issues
CTI BioPharma presents data from dose-finding PAC203 study of pacritinib
Read More
UNC-0638 in combination with HRI knockdown leads to induction of fetal hemoglobin
Read More
Novel TRIM24(COE) mouse model of metaplastic TNBC
Read More
Bacterial peptides can be gluten lookalikes
Read More
Long-term follow-up data presented from phase IIa study of KD-025 in cGvHD
Read More
Promising preclinical data presented for the HER2-targeting engineered toxin body MT-5111
Read More
Phase II data presented for efgartigimod in adults with primary ITP
Read More
AC Immune patents alpha-synuclein-targeting compounds for PET imaging
Read More
Lack of genomic diversity means actionable mutations are left undiscovered
Read More
XW Laboratories discloses Exp1 receptor antagonists
Read More
BeiGene identifies new MAP4K1 inhibitors
Read More
Qingdao Marine Biological Medicine Research presents EGF and FGF inhibitors
Read More
Dybly describes new BRD4 inhibitors
Read More
Principia advances PRN-1008 for pemphigus with accelerated enrollment in phase III study
Read More
New phase Ib study evaluates mavorixafor with ibrutinib for Waldenstrom's macroglobulinemia
Read More
Hookipa begins dosing in phase I/II trial of HB-201 for HPV16-positive cancers
Read More
FDA approves OncoImmune's IND for anti-CTLA-4 antibody ONC-392
Read More
BioXcel begins phase III program with BXCL-501 for agitation in schizophrenia and bipolar disorder
Read More
CTX-712: a novel promising CLK inhibitor for myeloid tumors
Read More
Anthos Therapeutics studies MAA-868 in phase II for atrial fibrillation
Read More